WO2019242339A1 - 一种包含第三信号受体的嵌合抗原受体及其应用 - Google Patents

一种包含第三信号受体的嵌合抗原受体及其应用 Download PDF

Info

Publication number
WO2019242339A1
WO2019242339A1 PCT/CN2019/077923 CN2019077923W WO2019242339A1 WO 2019242339 A1 WO2019242339 A1 WO 2019242339A1 CN 2019077923 W CN2019077923 W CN 2019077923W WO 2019242339 A1 WO2019242339 A1 WO 2019242339A1
Authority
WO
WIPO (PCT)
Prior art keywords
car
cells
intracellular region
scfv
cd3zeta
Prior art date
Application number
PCT/CN2019/077923
Other languages
English (en)
French (fr)
Inventor
杨选明
傅阳心
汪鑫
叶圣勤
李民
Original Assignee
上海隆耀生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海隆耀生物科技有限公司 filed Critical 上海隆耀生物科技有限公司
Priority to CN202210196195.6A priority Critical patent/CN114516922A/zh
Priority to EP19823459.3A priority patent/EP3812401A4/en
Priority to CN201980041282.0A priority patent/CN112673025B/zh
Priority to JP2020571580A priority patent/JP7433656B2/ja
Priority to KR1020217001094A priority patent/KR20210023991A/ko
Publication of WO2019242339A1 publication Critical patent/WO2019242339A1/zh
Priority to US17/127,283 priority patent/US11524034B2/en
Priority to US18/047,750 priority patent/US20230134345A1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464424—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Definitions

  • the invention relates to the technical field of cellular immunotherapy, in particular to a chimeric antigen receptor containing a third signal receptor and application thereof.
  • chimeric antigen receptor T cells were first proposed by Gross, Waks, and Eshhar in 1989. They expressed antibodies that recognize TNP on T cells, achieving the activation and effects of antigen-specific, non-MHC-restricted T cells. Enhancement and put forward the concept of the application of CAR-T technology in tumor treatment. According to this principle, embedding tumor-specific antibodies into T cells will give T cells new tumor-killing capabilities. Later, CAR-T technology was introduced into anti-tumor clinical trials. However, early CAR-T cells contained only the first signal because of their intracellular signalling domain, and the selected tumor type was solid tumor. The final clinical results were not Too ideal.
  • the structure of CAR consists of an extracellular antigen recognition domain, an extracellular hinge region, a transmembrane region, and an intracellular signaling domain.
  • the extracellular antigen recognition domain is usually composed of a single chain antibody, which specifically recognizes the surface molecules of tumor cell membranes, and may also be a ligand or receptor for certain tumor-specific antigens.
  • the extracellular hinge region is a space structure that separates the antigen recognition domain from the transmembrane region. The purpose is to provide a suitable spatial location so that the extracellular antigen recognition domain can maintain the correct structure before and after recognition of the antigen and conduct intracellularly. signal.
  • the transmembrane region is a domain that ensures the localization of CAR molecules on the membrane surface.
  • the intracellular signaling domain is a key part of mediating CAR signaling, usually one or several first signals (recognition of TCR and MHC-I-peptide complexes), and second signals (co-stimulatory receptors and co-stimulatory receptors). Body recognition).
  • the first generation CAR contains only the first signal
  • the second generation CAR has a first signal and a second signal
  • the third generation CAR has a first signal and two second signal domains.
  • CAR-T for B cell surface targeting molecules CD19 and CD20 prepared from patient's own blood cells has been relatively mature in the treatment of B cell leukemia, but although the response rate is high, there are a large number of recurrences. Tumor treatment efficiency is relatively low, which is related to the immunosuppressive microenvironment in solid tumors.
  • tumor microenvironment In solid tumors, there are a variety of immune cells, tumor cells and stromal cells, which together constitute the tumor microenvironment.
  • the tumor microenvironment is usually immunosuppressive. It can inhibit endogenous anti-tumor T cell responses or adoptive T cells (such as CAR-T) at multiple levels. For example, T cells are depleted and tumor-killing cells are lost. Function, eventually T cells are cleared. How to enhance the activation capacity of CAR-T in solid tumors so that it can fight against immunosuppression in the tumor microenvironment is an important idea and direction for the expansion of CAR-T to solid tumors.
  • CAR-T domains use novel regulatory molecules such as IL-12, 4 -1BBL, etc. In addition to affecting CAR-T, these molecules will also have non-specific activation of other non-CAR-T cells, potentially causing immune side effects.
  • the purpose of the present invention is to overcome the defects in the prior art, provide a chimeric antigen receptor of a third signal receptor and its application, and provide a CAR constructed from a recombinant expression vector such as the chimeric antigen receptor.
  • -T cells in which the activation of T cells is subjected to a first signal (recognition of TCR and MHC-I-peptide complex), a second signal (recognition of co-stimulatory receptors and co-stimulatory ligands), and 3
  • the regulation of signals cytokine receptor and cytokine recognition
  • these three synergistically achieve a large number of T cells to expand, exert effector functions, and clear infections or tumors.
  • the present invention adopts the following technical solutions:
  • a first object of the present invention is to provide a chimeric antigen receptor including a third signal receptor, and the structure of the chimeric antigen receptor is scFv (X)-(Y) CD3zeta-MN;
  • X includes a tumor-targeting antibody or a ligand and a receptor capable of specifically binding to the tumor
  • Y is an intracellular region of a co-stimulatory receptor selected from ICOS, CD28, CD27, HVEM, LIGHT, CD40L, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, CD226
  • M is the intracellular region of the gamma chain family cytokine receptor, the cytokine receptor is selected from IL2Ra, IL2Rb, IL4Ra, IL7Ra, IL9Ra, IL15Ra, IL21Ra
  • N is the intracellular region of IL2Rg.
  • the technical measures taken by the present invention also include:
  • the X is selected from the group consisting of an anti-CD19 antibody, an anti-CD20 antibody, an EGFR antibody, an HER2 antibody, an EGFRVIII antibody, an anti-PSMA antibody, an anti-BCMA antibody, an anti-CD22 antibody, and an anti-CD30 antibody. It can be understood that X may also be another protein capable of specifically binding to a tumor.
  • the X is an anti-CD20 antibody
  • the Y is a 4-1BB intracellular region
  • the M is selected from the group consisting of an IL2Rb intracellular region, an IL4Ra intracellular region, an IL7Ra intracellular region, an IL9Ra intracellular region, and an IL21Ra cell.
  • One of the inner zones are included in the X and the Y.
  • the scFv (X)-(Y) CD3zeta is scFv-antihCD20-20BBZ, the sequence of which is shown in SEQ ID No. 1; the sequence of the IL7Ra intracellular region is shown in SEQ ID No. 2; the IL2Rb The sequence of the intracellular region is shown in SEQ ID No. 3; the sequence of the intracellular region of IL4Ra is shown in SEQ ID No. 4; the sequence of the intracellular region of IL9Ra is shown in SEQ ID No. 5; The sequence of the region is shown in SEQ ID No. 6; the sequence of the IL2Rg intracellular region is shown in SEQ ID No. 7.
  • the extracellular hinge region of the chimeric antigen receptor is selected from a region of CD8a or IgG; the transmembrane region of the chimeric antigen receptor is selected from one of CD8a, CD28, CD137, or CD3.
  • a second object of the present invention is to provide a recombinant expression vector of any of the aforementioned chimeric antigen receptors.
  • a third object of the present invention is to provide a CAR-T cell constructed from a recombinant expression vector of any of the aforementioned chimeric antigen receptors.
  • a fourth object of the present invention is to provide a method for preparing the above CAR-T cells, which includes the following steps:
  • Step 1 Construction of lentiviral vector and virus production
  • ScFv (X)-(Y) CD3zeta, M and N form a fusion protein
  • lentiviral vectors are added at both ends, and co-transfection with the lentiviral packaging plasmid to obtain scFv (X)-(Y) CD3zeta-MN virus;
  • Step 2 Preparation of scFv (X)-(Y) CD3zeta-MN CAR-T cells;
  • the isolated and purified human PBMCs were cultured and infected with the scFv (X)-(Y) CD3zeta-MN virus obtained in step 1.
  • Cell expansion was performed under appropriate conditions to prepare scFv (X)-(Y) CD3zeta-MN.
  • CAR-T cells
  • X is a tumor-targeting antibody or other protein
  • Y is an intracellular region of a co-stimulatory receptor selected from ICOS, CD28, CD27, HVEM, LIGHT, CD40L, 4-1BB, OX40 , DR3, GITR, CD30, TIM1, SLAM, CD2, CD226
  • M is the intracellular region of the gamma chain family cytokine receptor selected from IL2Ra, IL2Rb, IL4Ra, IL7Ra, IL9Ra, IL15Ra, IL21Ra
  • N is the intracellular region of IL2Rg.
  • the technical measures adopted by the present invention further include:
  • the specific steps of constructing the lentiviral vector and virus production include: scFv (X)-(Y) CD3zeta, M and N are formed by an overlap PCR to form a fusion protein, and restriction sites are added at both ends to clone the lentiviral vector. ; The endotoxin-free clone was cloned correctly and transfected with the lentiviral packaging plasmid. The supernatant was collected at a predetermined time, and the virus was concentrated by centrifugation and centrifugation to obtain scFv (X)-(Y) CD3zeta-MN virus.
  • scFv (X)-(Y) CD3zeta M and N are formed by an overlap PCR to form a fusion protein, and EcoRI and BamHI restriction sites are added at both ends.
  • Clone the pCDH-MSCVEF vector clone the correctly cloned endotoxin-free clone and transfect 293X with the lentiviral packaging plasmid, collect the supernatant after 48 and 72 hours, and centrifuge at 25,000 RPM for 0.4 hours after 0.45 uM filtration to concentrate the virus to obtain scFv ( X)-(Y) CD3zeta-MN virus.
  • the specific steps of preparing the scFv (X)-(Y) CD3zeta-MN CAR-T cells include: after separating and purifying human PBMC, inoculating it into a culture plate with appropriate stimulation conditions, and culturing for a predetermined time, The scFv (X)-(Y) CD3zeta-MN virus produced in step 1 was infected, and the cells were expanded according to appropriate stimulation conditions. After 2 rounds of stimulation and expansion, the cells obtained were scFv (X)-(Y) CD3zeta -MN CAR-T cells.
  • the stimulating conditions of cultured, isolated and purified human PBMC are anti-hCD3 and anti-hCD28, and the stimulating conditions of expanded cells are stimulated with artificial antigen presenting cells or anti-hCD3 / 28 every 6 days.
  • the X is selected from an anti-CD19 antibody, an anti-CD20 antibody, an EGFR antibody, a HER2 antibody, and an EGFRVIII antibody.
  • the X is an anti-CD20 antibody
  • the Y is 4-1BB
  • the M is selected from one of IL2Rb, IL4Ra, IL7Ra, IL9Ra, and IL21Ra.
  • the scFv (X)-(Y) CD3zeta is scFv-antihCD20-20BBZ, the sequence of which is shown in SEQ ID No. 1; the sequence of the IL7Ra intracellular region is shown in SEQ ID No. 2; the IL2Rb The sequence of the intracellular region is shown in SEQ ID No. 3; the sequence of the intracellular region of IL4Ra is shown in SEQ ID No. 4; the sequence of the intracellular region of IL9Ra is shown in SEQ ID No. 5; The sequence of the region is shown in SEQ ID No. 6; the sequence of the IL2Rg intracellular region is shown in SEQ ID No. 7.
  • the lentiviral packaging plasmid in step 1 includes VSV-g, pMD, Gag / Pol, RSV-REV, and a Beckman ultracentrifuge and a SW28 rotor are used for centrifugation.
  • a fifth object of the present invention is to provide a preparation containing the above CAR-T cells or a CAR-T cell prepared by the above-mentioned preparation method; further, the preparation further includes a pharmaceutically acceptable diluent or excipient. Agent.
  • a sixth object of the present invention is to provide an application of the above-mentioned chimeric antigen receptor, the above-mentioned CAR-T cell, or the CAR-T cell prepared by the above-mentioned preparation method in preparing a medicine for treating or preventing tumor.
  • the tumor is a solid tumor
  • examples of the solid tumor include, but are not limited to, lymphoma, kidney tumor, neuroblastoma, germ cell tumor, osteosarcoma, chondrosarcoma, soft tissue sarcoma, liver tumor, thymoma, Pulmonary blastoma, pancreatoblastoma, hemangioma, etc.
  • the present invention has the following beneficial effects:
  • the CAR-T cells according to the present invention significantly improve the tumor killing ability and expansion ability, and significantly improve the killing ability of solid tumors / metastatic tumors.
  • the CAR-T cells according to the invention include a third signal receptor (IL2Ra , IL2Rb, IL4Ra, IL7Ra, IL9Ra, IL15Ra, IL21Ra, etc.), which are not conventionally used ligands or secretory factors, such as the third signal receptor IL7Ra, which is mainly expressed in memory CD4 and CD8 T cells. Long-term survival and the formation of memory T cells have an important role. Integrating the third signal receptor signal into CAR-T has the potential to enhance the effect, and only affects CAR-T cells, reducing the immune side effects risks of.
  • the present invention improves the activation capacity and survival capacity of CAR-T cells in tumors compared with the currently used CAR-T technology, and the activation capacity and expansion capacity are significantly improved. Enhancement, thereby increasing the efficacy of CAR-T cells to have more excellent anti-tumor efficacy.
  • FIG. 1 is a schematic diagram illustrating a molecular structure of a chimeric antigen receptor (CAR) containing a third signal receptor in each embodiment of the present invention
  • FIG. 2 is a schematic diagram of a virus titer measured after 293 cells were infected by BBZIL2RbIL2Rg virus according to an embodiment of the present invention
  • FIG. 3 is a schematic diagram of a virus titer measured after 293 cells were infected by BBZIL4RaIL2Rg virus according to an embodiment of the present invention
  • FIG. 4 is a schematic diagram of a virus titer measured after 293 cells were infected by BBZIL7RaIL2Rg virus according to an embodiment of the present invention
  • FIG. 5 is a schematic diagram of a virus titer measured after BBZIL9RaIL2Rg virus infects 293 cells according to an embodiment of the present invention
  • FIG. 6 is a schematic diagram of a virus titer measured after 293 cells were infected by BBZIL21RaIL2Rg virus according to an embodiment of the present invention
  • FIG. 7 is a schematic diagram of the results of phenotypic analysis of BBZ CAR-T cells and BBZIL2RbIL2Rg CAR-T cells in an embodiment of the present invention
  • FIG. 8 is a schematic diagram of the results of phenotypic analysis of BBZ CAR-T cells and BBZIL4RaIL2Rg CAR-T cells in an embodiment of the present invention
  • FIG. 9 is a schematic diagram of the results of phenotypic analysis of BBZ CAR-T cells and BBZIL7RaIL2Rg CAR-T cells in an embodiment of the present invention.
  • FIG. 10 is a schematic diagram of the results of phenotypic analysis of BBZ CAR-T cells and BBZIL9RaIL2Rg CAR-T cells in an embodiment of the present invention
  • FIG. 11 is a schematic diagram of the results of phenotypic analysis of BBZ CAR-T cells and BBZIL21RaIL2Rg CAR-T cells in an embodiment of the present invention
  • FIG. 12 is a schematic diagram of the expansion capacity of BBZ CAR-T cells and BBZIL7RaIL2Rg CAR-T cells in an embodiment of the present invention
  • FIG. 13 is a schematic diagram of tumor killing ability of BBZ CAR-T cells and BBZIL7RaIL2Rg CAR-T cells in an embodiment of the present invention
  • FIG. 14 is a schematic diagram of the anti-tumor ability of BBZ CAR-T cells and BBZIL7RaIL2Rg CAR-T cells in an embodiment of the present invention
  • FIG. 15 is a schematic diagram of the in vivo viability of BBZ CAR-T cells and BBZIL7RaIL2Rg CAR-T cells in an embodiment of the present invention.
  • the present invention provides a chimeric antigen receptor including a third signal receptor.
  • the structure of the chimeric antigen receptor is scFv (X)-(Y) CD3zeta-MN; wherein X is a tumor-targeting antibody or other protein ; Y is the intracellular region of a co-stimulatory receptor selected from the group consisting of ICOS, CD28, CD27, HVEM, LIGHT, CD40L, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, CD226; M is the intracellular region of the gamma chain family cytokine receptor selected from IL2Ra, IL2Rb, IL4Ra, IL7Ra, IL9Ra, IL15Ra, IL21Ra; N is the IL2Rg intracellular region.
  • the invention also relates to a CAR-T cell constructed from any of the above-mentioned chimeric antigen receptor recombinant expression vectors and a preparation method thereof, a preparation containing the CAR-T cell, and an application of the CAR-T cell.
  • the chimeric antigen receptor (CAR) molecules containing a third signal receptor are BBZIL2RbIL2Rg, BBZIL4RaIL2Rg, BBZIL7RaIL2Rg, BBZIL9RaIL2Rg, and BBZIL21RaIL2Rg, and their structures are shown in FIG. 1.
  • the preparation of the 20BBZIL2RbIL2Rg CAR-T cells described in this example includes the following steps:
  • ScFv-antihCD20-20BBZ (SEQ ID No. 1), IL2Rb intracellular region (SEQ ID No. 3) and IL2Rg intracellular region (SEQ ID No. 7) were formed by overlapping PCR to form a fusion protein, and EcoRI and BamHI were added at both ends.
  • the pCDH-MSCVEF vector was cloned at the restriction site. Endotoxin-free clones that were sequenced correctly were cloned with lentiviral packaging plasmids (VSV-g, pMD, Gag / Pol, RSV-REV) to transfect 293X. Supernatants were collected after 48 and 72 hours.
  • the Beckman ultracentrifuge and SW28 rotor were centrifuged at 25,000 RPM for 2 hours to concentrate the virus, namely pCDH-MSCVEF-20BBZIL2RbIL2Rg virus (referred to as 20BBZIL2RbIL2Rg virus) for subsequent CAR-T cell production.
  • pCDH-MSCVEF-20BBZ virus (20BBZ virus for short) was produced, and the obtained 20BBZIL2RbIL2Rg virus was used to infect 293 cells, and the virus titer was measured, as shown in FIG. 2.
  • the preparation of the 20BBZIL4RaIL2Rg CAR-T cells described in this example includes the following steps:
  • ScFv-antihCD20-20BBZ (SEQ ID No. 1), IL4Ra intracellular region (SEQ ID No. 4) and IL2Rg intracellular region (SEQ ID No. 7) were formed by an overlap PCR to form a fusion protein, and EcoRI and BamHI were added at both ends.
  • the pCDH-MSCVEF vector was cloned at the restriction site. Endotoxin-free clones that were sequenced correctly were cloned with lentiviral packaging plasmids (VSV-g, pMD, Gag / Pol, RSV-REV) to transfect 293X. Supernatants were collected after 48 and 72 hours.
  • the Beckman ultracentrifuge and SW28 rotor were centrifuged at 25,000 RPM for 2 hours to concentrate the virus, namely pCDH-MSCVEF-20BBZIL4RaIL2Rg virus (referred to as 20BBZIL4RaIL2Rg virus) for subsequent CAR-T cell production.
  • pCDH-MSCVEF-20BBZ virus 20BBZ virus for short
  • 20BBZIL4RaIL2Rg virus was used to infect 293 cells, and the virus titer was measured, as shown in FIG. 3.
  • the preparation of the 20BBZIL7RaIL2Rg CAR-T cells described in this example includes the following steps:
  • ScFv-antihCD20-20BBZ (SEQ ID No. 1), IL7Ra intracellular region (SEQ ID No. 2) and IL2Rg intracellular region (SEQ ID No. 7) were formed by an overlap PCR to form a fusion protein, and EcoRI and BamHI were added at both ends.
  • the pCDH-MSCVEF vector was cloned at the restriction site. Endotoxin-free clones that were sequenced correctly were cloned with lentiviral packaging plasmids (VSV-g, pMD, Gag / Pol, RSV-REV) to transfect 293X. Supernatants were collected after 48 and 72 hours.
  • the Beckman ultracentrifuge and SW28 rotor were centrifuged at 25,000 RPM for 2 hours to concentrate the virus, namely pCDH-MSCVEF-20BBZIL7RaIL2Rg virus (referred to as 20BBZIL7RaIL2Rg virus) for subsequent CAR-T cell production.
  • the control pCDH-MSCVEF-20BBZ virus (20BBZ virus for short) was produced, and the obtained 20BBZIL7RaIL2Rg virus was used to infect 293 cells, and the virus titer was measured, as shown in FIG. 4.
  • the preparation of the 20BBZIL9RaIL2Rg CAR-T cells described in this example includes the following steps:
  • ScFv-antihCD20-20BBZ (SEQ ID No. 1), IL9Ra intracellular region (SEQ ID No. 5) and IL2Rg intracellular region (SEQ ID No. 7) were formed by overlapping PCR to form a fusion protein, and EcoRI and BamHI were added at both ends.
  • the pCDH-MSCVEF vector was cloned at the restriction site. Endotoxin-free clones that were sequenced correctly were cloned with lentiviral packaging plasmids (VSV-g, pMD, Gag / Pol, RSV-REV) to transfect 293X. Supernatants were collected after 48 and 72 hours.
  • the Beckman ultracentrifuge and SW28 rotor were centrifuged at 25,000 RPM for 2 hours to concentrate the virus, namely pCDH-MSCVEF-20BBZIL9RaIL2Rg virus (referred to as 20BBZIL9RaIL2Rg virus) for subsequent CAR-T cell production.
  • pCDH-MSCVEF-20BBZ virus 20BBZ virus for short
  • 20BBZIL9RaIL2Rg virus was used to infect 293 cells, and the virus titer was measured, as shown in FIG. 5.
  • the preparation of the 20BBZIL21RaIL2Rg CAR-T cells described in this example includes the following steps:
  • ScFv-antihCD20-20BBZ (SEQ ID No. 1), IL21Ra intracellular region (SEQ ID No. 6) and IL2Rg intracellular region (SEQ ID No. 7) were formed by overlapping PCR to form a fusion protein, and EcoRI and BamHI were added at both ends.
  • the pCDH-MSCVEF vector was cloned at the restriction site. Endotoxin-free clones that were sequenced correctly were cloned with lentiviral packaging plasmids (VSV-g, pMD, Gag / Pol, RSV-REV) to transfect 293X. Supernatants were collected after 48 and 72 hours.
  • the Beckman ultracentrifuge and SW28 rotor were centrifuged at 25,000 RPM for 2 hours to concentrate the virus, namely pCDH-MSCVEF-20BBZIL21RaIL2Rg virus (referred to as 20BBZIL21RaIL2Rg virus) for subsequent CAR-T cell production.
  • pCDH-MSCVEF-20BBZ virus 20BBZ virus for short
  • 20BBZIL21RaIL2Rg virus was used to infect 293 cells, and the virus titer was measured, as shown in FIG. 6.
  • the 20BBZ CAR-T cells and 20BBZIL7RaIL2Rg CAR-T cells prepared in step 2 in Example 3 were continuously cultured for 14 days, and stimulated with artificial antigen presenting cells every 6 days. The cell count was shown in FIG. 12. It can be seen from the figure that 20BBZIL7RaIL2Rg CAR-T cells have stronger proliferation ability than 20BBZCAR-T cells.
  • 20BBZ CAR-T cells and 20BBZIL7RaIL2Rg CAR-T cells prepared in step 2 in Example 3 were seeded into a 96-well plate, and Raji tumors were added according to CAR-T: tumor cell ratios 1: 1, 1: 2, and 1: 4. Cells were compared for survival ratio of tumor cells after 24 and 48 hours. The results are shown in FIG. 13. It can be seen from the figure that 20BBZIL7RaIL2Rg CAR-T cells have similar tumor-killing ability compared to 20BBZ CAR-T cells.
  • the present invention enables CAR-T cells to activate, survive, and expand CAR
  • the enhancement ability is significantly enhanced, and it has more excellent anti-tumor efficacy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明提供了结构为scFv(X)-(Y)CD3zeta-MN的嵌合抗原受体，其中，X包括肿瘤靶向抗体或能与肿瘤特异结合的配体、受体；Y为共刺激受体的胞内区，所述共刺激受体选自ICOS、CD28、CD27、HVEM、LIGHT、CD40L、4-1BB、OX40、DR3、GITR、CD30、TIM1、SLAM、CD2、CD226；M为gamma chain家族细胞因子受体的胞内区，所述细胞因子受体选自IL2Ra、IL2Rb、IL4Ra、IL7Ra、IL9Ra、IL15Ra、IL21Ra；N为IL2Rg胞内区。本发明还提供了由上述嵌合抗原受体的重组表达载体构建的CAR-T细胞及其制备方法和应用。本发明所述的CAR-T细胞显著提高了肿瘤杀伤能力和扩增能力。

Description

一种包含第三信号受体的嵌合抗原受体及其应用 技术领域
本发明涉及细胞免疫治疗技术领域，尤其涉及一种包含第三信号受体的嵌合抗原受体及其应用。
背景技术
利用免疫学治疗手段来攻克肿瘤，一直是免疫学在转化医学方面应用的重要方向。随着各种组学(基因组学，蛋白组学等)的发展，肿瘤细胞由于突变产生的免疫原性得到了广泛的认可，这为肿瘤免疫治疗奠定了理论的基础。同时，随着肿瘤免疫学研究自身的积累，肿瘤免疫治疗近期取得了巨大的进步，一系列新的免疫治疗手段逐步进入临床。当前的肿瘤免疫学研究，奠定了T细胞杀伤在肿瘤免疫治疗中的中心地位，而嵌和抗原受体T细胞(CAR-T细胞)就是结合了抗体的靶向识别和T细胞的肿瘤杀伤功能，人工修饰生成的肿瘤杀伤细胞。
嵌和抗原受体T细胞的概念最早在1989年被Gross，Waks和Eshhar提出，他们将识别TNP的抗体表达在T细胞上，实现了抗原特异性的、非MHC限制的T细胞的活化和效应的增强，并提出了CAR-T技术在肿瘤治疗中的应用的概念。根据这一原理，将具有肿瘤特异性的抗体嵌入T细胞，将赋予T细胞新的杀瘤能力。之后，CAR-T技术被引入到抗肿瘤临床试验中，但早期的CAR-T细胞由于其胞内信号传递域仅含有第一信号，而且选择的肿瘤类型为实体瘤，最终的临床结果都不太理想。在2008年，Fred Hutchison肿瘤研究所等机构使用CAR-T对B细胞淋巴瘤来进行治疗，虽然治疗结果不太理想，但这一临床实验的关键在于证实了以表达CD20的B细胞作为靶点的CAR-T治疗是相对安全的。随后，在2010年NCI报道了一例B细胞淋巴瘤治疗成功的病例，利用针对CD19的CAR-T，病人的淋巴瘤得到控制，正常B细胞也被清除，血清Ig显著降低，为CAR-T治疗B细胞来源的淋巴瘤的有效性提供了理论和实际的支持。在2011年，美国宾夕法尼亚大学的的Carl June博士领导的团队将特异性识别CD19的CAR-T用于B细胞来源的慢性淋巴细胞白血病的治疗，显示了“治愈” 的疗效，随后在复发难治性急性淋巴细胞白血病展开临床实验，也取得了良好的疗效。由于这一突破性的进展以及其他免疫调控手段的发展，Science杂志将肿瘤免疫治疗评为了2013年科技突破进展的第一名。这一成功在世界各国引起了广泛的影响，各国开始大量开展基于CAR-T的科学研究和肿瘤治疗的临床试验。
CAR的结构由胞外抗原识别结构域，胞外铰链区，跨膜区和胞内的信号传导结构域组成。胞外的抗原识别域通常是由单链抗体组成，特异性识别肿瘤细胞膜表面分子，也可以是某些肿瘤特异抗原的配体或受体等。胞外铰链区是一段用于隔开抗原识别域和跨膜区的空间结构，其目的是为了提供合适的空间位置，使得胞外抗原识别域能够在识别抗原前后维持正确的结构并传导胞内信号。跨膜区是为了保证CAR分子在膜表面定位的结构域。胞内信号传导结构域是介导CAR信号传导的关键部分，通常是一个或几个第一信号(TCR和MHC-I-peptide复合物识别)，第二信号(共刺激受体和共刺激配体识别)的组合。第一代CAR只含有第一信号，第二代CAR有一个第一信号和一个第二信号，第三代CAR有一个第一信号和两个第二信号结构域。虽然CAR-T在针对B细胞来源的白血病治疗中获得了巨大的成功，但是其相对较高的复发率以及对实体瘤的低有效率是当前的重要挑战。因此发展新一代的高效CAR-T是目前临床所急需的。除了第三代CAR-T，目前还有其他新的CAR-T设计策略，即在第二代CAR-T的基础上引入了新的独立于CAR的调节分子，以进一步增强CAR-T的功能。
利用病人自体血液细胞制备的针对B细胞表面靶向分子CD19、CD20的CAR-T在B细胞白血病治疗中的应用已相对成熟，但虽然响应率高，但是存在大量的复发现象，此外对实体淋巴瘤的治疗效率相对较低，这与实体肿瘤中的免疫抑制微环境有关。
在实体肿瘤中，存在多种免疫细胞、肿瘤细胞和基质细胞，共同组成肿瘤微环境。肿瘤微环境通常是免疫抑制的，能够对内源的抗肿瘤T细胞反应或过继性的T细胞(譬如CAR-T)在多种层次进行抑制，譬如，导致T细胞发生耗竭，失去杀伤肿瘤的功能，最终T细胞被清除。如何增强CAR-T在实体瘤中的活化能力，使其能够对抗肿瘤微环境中的免疫抑制，是扩增CAR-T到实体瘤治疗的重要思路和方向。
而当前临床使用的CAR-T结构域，在肿瘤杀伤能力和扩增能力上还存在不 足，在控制实体肿瘤/转移肿瘤上疗效较差，部分CAR-T采用新型调控分子如IL-12，4-1BBL等，这些分子除了影响CAR-T，也会对其他非CAR-T细胞产生非特异的活化作用，有造成免疫副作用的潜在可能。
发明内容
本发明的目的在于克服现有技术中的缺陷，提供一种第三信号受体的嵌合抗原受体及其应用，并提供一种由如该嵌合抗原受体的重组表达载体构建的CAR-T细胞，在该CAR-T细胞中T细胞的活化受到第1信号(TCR和MHC-I-peptide复合物识别)，第2信号(共刺激受体和共刺激配体识别)和第3信号(细胞因子受体和细胞因子识别)的调控，这三者协同作用达到T细胞大量扩增，发挥效应功能，清除感染或肿瘤。
为实现上述目的，本发明采用如下技术方案：
本发明的第一个目的是提供一种包含第三信号受体的嵌合抗原受体，所述嵌合抗原受体的结构为scFv(X)-(Y)CD3zeta-MN；
其中，X包括肿瘤靶向抗体或能与肿瘤特异结合的配体、受体；Y为共刺激受体的胞内区，所述共刺激受体选自ICOS、CD28、CD27、HVEM、LIGHT、CD40L、4-1BB、OX40、DR3、GITR、CD30、TIM1、SLAM、CD2、CD226；M为gamma chain家族细胞因子受体的胞内区，所述细胞因子受体选自IL2Ra、IL2Rb、IL4Ra、IL7Ra、IL9Ra、IL15Ra、IL21Ra；N为IL2Rg胞内区。
为了进一步优化上述嵌合抗原受体，本发明采取的技术措施还包括：
进一步地，所述X选自anti-CD19抗体、anti-CD20抗体、EGFR抗体、HER2抗体、EGFRVIII抗体、anti-PSMA抗体、anti-BCMA抗体、anti-CD22抗体，anti-CD30抗体。可理解的是，X还可为能与肿瘤特异结合的其他蛋白。
进一步地，所述X为anti-CD20抗体，所述Y为4-1BB胞内区，所述M选自IL2Rb胞内区、IL4Ra胞内区、IL7Ra胞内区、IL9Ra胞内区、IL21Ra胞内区中的一种。
进一步地，所述scFv(X)-(Y)CD3zeta为scFv-antihCD20-20BBZ，其序列如SEQID No.1所示；所述IL7Ra胞内区的序列如SEQID No.2所示；所述IL2Rb胞内区的序列如SEQID No.3所示；所述IL4Ra胞内区的序列如SEQID No.4所 示；所述IL9Ra胞内区的序列如SEQID No.5所示；所述IL21Ra胞内区的序列如SEQID No.6所示；所述IL2Rg胞内区的序列如SEQID No.7所示。
其中上述各序列具体如下：
SEQ ID No.1：
Figure PCTCN2019077923-appb-000001
SEQ ID No.2：
Figure PCTCN2019077923-appb-000002
SEQ ID No.3
Figure PCTCN2019077923-appb-000003
SEQ ID No.4：
Figure PCTCN2019077923-appb-000004
Figure PCTCN2019077923-appb-000005
SEQ ID No.5：
Figure PCTCN2019077923-appb-000006
SEQ ID No.6：
Figure PCTCN2019077923-appb-000007
SEQ ID No.7：
Figure PCTCN2019077923-appb-000008
进一步地，所述嵌合抗原受体的胞外铰链区选自CD8a或IgG的一段区域；所述嵌合抗原受体的跨膜区选自CD8a、CD28、CD137或CD3中的一个。
本发明的第二个目的是提供一种任一上述的嵌合抗原受体的重组表达载体。
本发明的第三个目的是提供一种由任一上述的嵌合抗原受体的重组表达载体构建的CAR-T细胞。
本发明的第四个目的是提供一种上述CAR-T细胞的制备方法，其包括以下步骤：
步骤一、慢病毒载体的构建及病毒生产；
将scFv(X)-(Y)CD3zeta，M和N形成融合蛋白，两端加入慢病毒载体，并和慢病毒包装质粒共同转染，获得scFv(X)-(Y)CD3zeta-MN病毒；
步骤二、scFv(X)-(Y)CD3zeta-MN CAR-T细胞的制备；
分离纯化后的人PBMC经过培养后，感染步骤一获得的scFv(X)-(Y)CD3zeta-MN病毒，在合适的条件下进行细胞扩增，制备scFv(X)-(Y)CD3zeta-MN CAR-T细胞；
其中，其中，X为肿瘤靶向抗体或其他蛋白；Y为共刺激受体的胞内区，所述共刺激受体选自ICOS、CD28、CD27、HVEM、LIGHT、CD40L、4-1BB、OX40、DR3、GITR、CD30、TIM1、SLAM、CD2、CD226；M为gamma chain家族细胞因子受体的胞内区，所述细胞因子受体选自IL2Ra、IL2Rb、IL4Ra、IL7Ra、IL9Ra、IL15Ra、IL21Ra；N为IL2Rg胞内区。
为了进一步优化上述CAR-T细胞的制备方法，本发明采取的技术措施还包括：
进一步地，所述慢病毒载体的构建及病毒生产的具体步骤包括：将scFv(X)-(Y)CD3zeta，M和N通过overlap PCR形成融合蛋白，两端加入酶切位点克隆慢病毒载体；将测序正确的克隆无内毒素大提，和慢病毒包装质粒共同转染，预定时间收取上清，过滤、离心浓缩病毒，获得scFv(X)-(Y)CD3zeta-MN病毒。
更进一步地，所述慢病毒载体的构建及病毒生产的具体步骤为：将scFv(X)-(Y)CD3zeta，M和N通过overlap PCR形成融合蛋白，两端加入EcoRI和BamHI酶切位点克隆pCDH-MSCVEF载体；将测序正确的克隆无内毒素大提，和慢病毒包装质粒共同转染293X，48和72小时后收取上清，0.45uM过滤后25000RPM离心2小时浓缩病毒，获得scFv(X)-(Y)CD3zeta-MN病毒。
进一步地，所述scFv(X)-(Y)CD3zeta-MN CAR-T细胞的制备的具体步骤包括：将人PBMC经过分离纯化后，接种到具有合适刺激条件的培养板，培养预定时间后，感染步骤一生产的scFv(X)-(Y)CD3zeta-MN病毒，按照合适的刺激条 件进行细胞扩增，经过2轮刺激扩增后，获得的细胞即为scFv(X)-(Y)CD3zeta-MN CAR-T细胞。
进一步地，培养分离纯化后的人PBMC的刺激条件为anti-hCD3和anti-hCD28，扩增细胞的刺激条件为每6天使用人工抗原呈递细胞或anti-hCD3/28刺激。
更进一步地，所述scFv(X)-(Y)CD3zeta-MN CAR-T细胞的制备的具体步骤为：将人PBMC经过Stemcell T细胞分离试剂盒纯化后，接种到anti-hCD3和anti-hCD28包被的96孔培养板，2天后，按照MOI＝10-20感染步骤一生产的scFv(X)-(Y)CD3zeta-MN病毒，1天后换液继续细胞培养，按照每6天使用人工抗原呈递细胞或anti-hCD3/28刺激，经过2轮刺激后，所得细胞即为scFv(X)-(Y)CD3zeta-MN CAR-T。
进一步地，所述X选自anti-CD19抗体、anti-CD20抗体、EGFR抗体、HER2抗体、EGFRVIII抗体。
进一步地，所述X为anti-CD20抗体，所述Y为4-1BB，所述M选自IL2Rb、IL4Ra、IL7Ra、IL9Ra、IL21Ra中的一种。
进一步地，所述scFv(X)-(Y)CD3zeta为scFv-antihCD20-20BBZ，其序列如SEQID No.1所示；所述IL7Ra胞内区的序列如SEQID No.2所示；所述IL2Rb胞内区的序列如SEQID No.3所示；所述IL4Ra胞内区的序列如SEQID No.4所示；所述IL9Ra胞内区的序列如SEQID No.5所示；所述IL21Ra胞内区的序列如SEQID No.6所示；所述IL2Rg胞内区的序列如SEQID No.7所示。
进一步地，所述步骤一中慢病毒包装质粒包括VSV-g，pMD Gag/Pol，RSV-REV，离心使用贝克曼超速离心机和SW28转头。
本发明的第五个目的是提供一种含有上述CAR-T细胞或含有由上述制备方法制得的的CAR-T细胞的制剂；进一步地，所述制剂还包括药用的稀释剂或赋形剂。
本发明的第六个目的是提供一种上述嵌合抗原受体、上述CAR-T细胞或由上述制备方法制得的的CAR-T细胞在制备治疗或预防肿瘤药物中的应用。
进一步地，所述肿瘤为实体肿瘤，该实体肿瘤的例子包括但不限于，淋巴瘤、肾脏肿瘤、神经母细胞瘤、生殖细胞瘤、骨肉瘤、软骨肉瘤、软组织肉瘤、肝脏 肿瘤、胸腺瘤、肺母细胞瘤、胰母细胞瘤、血管瘤等。
与现有技术相比，本发明具有以下有益效果：
本发明所述的CAR-T细胞显著提高了肿瘤杀伤能力和扩增能力，显著提高的实体肿瘤/转移肿瘤的杀伤能力；本发明所述的CAR-T细胞，包含第三信号受体(IL2Ra、IL2Rb、IL4Ra、IL7Ra、IL9Ra、IL15Ra、IL21Ra等)，其不是常规所用的配体或分泌因子，例如第三信号的受体IL7Ra，主要表达在记忆性的CD4和CD8T细胞，对T细胞的长期存活和记忆性T细胞的形成有着重要作用，将第三信号受体信号整合在CAR-T中，具有潜在的增强效应的功能，且只对CAR-T细胞有作用，降低了造成免疫副作用的风险。
本发明通过构建新型含第三信号受体的CAR-T细胞，相对目前临床使用的CAR-T技术，其提高CAR-T细胞在肿瘤中的活化能力和存活能力，活化能力和扩增能力显著增强，从而提高CAR-T细胞疗效，以具有更优异的抗肿瘤疗效。
附图说明
图1为本发明各实施例中含有第三信号受体的嵌合抗原受体(CAR)分子结构的说明示意图；
图2为本发明一实施例中BBZIL2RbIL2Rg病毒感染293细胞后测得的病毒滴度的示意图；
图3为本发明一实施例中BBZIL4RaIL2Rg病毒感染293细胞后测得的病毒滴度的示意图；
图4为本发明一实施例中BBZIL7RaIL2Rg病毒感染293细胞后测得的病毒滴度的示意图；
图5为本发明一实施例中BBZIL9RaIL2Rg病毒感染293细胞后测得的病毒滴度的示意图；
图6为本发明一实施例中BBZIL21RaIL2Rg病毒感染293细胞后测得的病毒滴度的示意图；
图7为本发明一实施例中BBZ CAR-T细胞和BBZIL2RbIL2Rg CAR-T细胞表型分析的结果示意图；
图8为本发明一实施例中BBZ CAR-T细胞和BBZIL4RaIL2Rg CAR-T细胞 表型分析的结果示意图；
图9为本发明一实施例中BBZ CAR-T细胞和BBZIL7RaIL2Rg CAR-T细胞表型分析的结果示意图；
图10为本发明一实施例中BBZ CAR-T细胞和BBZIL9RaIL2Rg CAR-T细胞表型分析的结果示意图；
图11为本发明一实施例中BBZ CAR-T细胞和BBZIL21RaIL2Rg CAR-T细胞表型分析的结果示意图；
图12为本发明一实施例中BBZ CAR-T细胞和BBZIL7RaIL2Rg CAR-T细胞的扩增能力的示意图；
图13为本发明一实施例中BBZ CAR-T细胞和BBZIL7RaIL2Rg CAR-T细胞的肿瘤杀伤能力的示意图；
图14为本发明一实施例中BBZ CAR-T细胞和BBZIL7RaIL2Rg CAR-T细胞的抗肿瘤能力的示意图；
图15为本发明一实施例中BBZ CAR-T细胞和BBZIL7RaIL2Rg CAR-T细胞的体内存活能力的示意图。
具体实施方式
本发明提供一种包含第三信号受体的嵌合抗原受体，该嵌合抗原受体的结构为scFv(X)-(Y)CD3zeta-MN；其中，X为肿瘤靶向抗体或其他蛋白；Y为共刺激受体的胞内区，所述共刺激受体选自ICOS、CD28、CD27、HVEM、LIGHT、CD40L、4-1BB、OX40、DR3、GITR、CD30、TIM1、SLAM、CD2、CD226；M为gamma chain家族细胞因子受体的胞内区，所述细胞因子受体选自IL2Ra、IL2Rb、IL4Ra、IL7Ra、IL9Ra、IL15Ra、IL21Ra；N为IL2Rg胞内区。本发明还涉及一种由任一上述的嵌合抗原受体的重组表达载体构建的CAR-T细胞及其制备方法，含有该CAR-T细胞的制剂以及该CAR-T细胞的应用。
下面结合附图和实施例，对本发明的具体实施方式作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案，而不能以此来限制本发明的保护范围。
本发明下述实施例所涉及的含有第三信号受体的嵌合抗原受体(CAR)分子 分别为BBZIL2RbIL2Rg、BBZIL4RaIL2Rg、BBZIL7RaIL2Rg、BBZIL9RaIL2Rg、BBZIL21RaIL2Rg，其结构如图1所示。
实施例1-20BBZIL2RbIL2Rg CAR-T细胞的制备
本实施例所述的20BBZIL2RbIL2Rg CAR-T细胞的制备包括以下步骤：
1.慢病毒载体pCDH-MSCVEF-20BBZIL2RbIL2Rg的构建及病毒生产
将scFv-antihCD20-20BBZ(SEQ ID No.1)，IL2Rb胞内区(SEQ ID No.3)和IL2Rg胞内区(SEQ ID No.7)通过overlap PCR形成融合蛋白，两端加入EcoRI和BamHI酶切位点克隆pCDH-MSCVEF载体。将测序正确的克隆无内毒素大提，和慢病毒包装质粒(VSV-g，pMD Gag/Pol，RSV-REV)共同转染293X，48和72小时后收取上清，0.45uM过滤后，使用贝克曼超速离心机和SW28转头，25000RPM离心2小时浓缩病毒，即为pCDH-MSCVEF-20BBZIL2RbIL2Rg病毒(简称为20BBZIL2RbIL2Rg病毒)，用于后续CAR-T细胞生产。同时生产对照pCDH-MSCVEF-20BBZ病毒(简称20BBZ病毒)，将所得20BBZIL2RbIL2Rg病毒感染293细胞，测得病毒滴度，如图2所示。
2. 20BBZIL2RbIL2Rg CAR-T细胞和20BBZ CAR-T细胞的制备
将人PBMC经过Stemcell T细胞分离试剂盒纯化后，接种到anti-hCD3和anti-hCD28包被的96孔培养板，2天后，按照MOI＝10-20感染20BBZ病毒和20BBZIL2RbIL2Rg病毒，1天后换液继续细胞培养，按照每6天使用人工抗原呈递细胞或anti-hCD3/28刺激，经过2轮刺激后，所得细胞即为20BBZ CAR-T细胞和20BBZIL2RbIL2Rg CAR-T细胞，用于后续实验和表型分析。如图7所示，所得细胞为CAR阳性。
实施例2-20BBZIL4RaIL2Rg CAR-T细胞的制备
本实施例所述的20BBZIL4RaIL2Rg CAR-T细胞的制备包括以下步骤：
1.慢病毒载体pCDH-MSCVEF-20BBZIL4RaIL2Rg的构建及病毒生产
将scFv-antihCD20-20BBZ(SEQ ID No.1)，IL4Ra胞内区(SEQ ID No.4)和IL2Rg胞内区(SEQ ID No.7)通过overlap PCR形成融合蛋白，两端加入EcoRI和BamHI酶切位点克隆pCDH-MSCVEF载体。将测序正确的克隆无内毒素大提，和慢病毒包装质粒(VSV-g，pMD Gag/Pol，RSV-REV)共同转染293X，48和72小时后收取上清，0.45uM过滤后，使用贝克曼超速离心机和SW28转头， 25000RPM离心2小时浓缩病毒，即为pCDH-MSCVEF-20BBZIL4RaIL2Rg病毒(简称为20BBZIL4RaIL2Rg病毒)，用于后续CAR-T细胞生产。同时生产对照pCDH-MSCVEF-20BBZ病毒(简称20BBZ病毒)，将所得20BBZIL4RaIL2Rg病毒感染293细胞，测得病毒滴度，如图3所示。
2. 20BBZIL4RaIL2Rg CAR-T细胞和20BBZ CAR-T细胞的制备
将人PBMC经过Stemcell T细胞分离试剂盒纯化后，接种到anti-hCD3和anti-hCD28包被的96孔培养板，2天后，按照MOI＝10-20感染20BBZ病毒和20BBZIL4RaIL2Rg病毒，1天后换液继续细胞培养，按照每6天使用人工抗原呈递细胞或anti-hCD3/28刺激，经过2轮刺激后，所得细胞即为20BBZ CAR-T细胞和20BBZIL4RaIL2Rg CAR-T细胞，用于后续实验和表型分析。如图8所示，所得细胞为CAR阳性。
实施例3-20BBZIL7RaIL2Rg CAR-T细胞的制备
本实施例所述的20BBZIL7RaIL2Rg CAR-T细胞的制备包括以下步骤：
1.慢病毒载体pCDH-MSCVEF-20BBZIL7RaIL2Rg的构建及病毒生产
将scFv-antihCD20-20BBZ(SEQ ID No.1)，IL7Ra胞内区(SEQ ID No.2)和IL2Rg胞内区(SEQ ID No.7)通过overlap PCR形成融合蛋白，两端加入EcoRI和BamHI酶切位点克隆pCDH-MSCVEF载体。将测序正确的克隆无内毒素大提，和慢病毒包装质粒(VSV-g，pMD Gag/Pol，RSV-REV)共同转染293X，48和72小时后收取上清，0.45uM过滤后，使用贝克曼超速离心机和SW28转头，25000RPM离心2小时浓缩病毒，即为pCDH-MSCVEF-20BBZIL7RaIL2Rg病毒(简称为20BBZIL7RaIL2Rg病毒)，用于后续CAR-T细胞生产。同时生产对照pCDH-MSCVEF-20BBZ病毒(简称20BBZ病毒)，将所得20BBZIL7RaIL2Rg病毒感染293细胞，测得病毒滴度，如图4所示。
2. 20BBZIL7RaIL2Rg CAR-T细胞和20BBZ CAR-T细胞的制备
将人PBMC经过Stemcell T细胞分离试剂盒纯化后，接种到anti-hCD3和anti-hCD28包被的96孔培养板，2天后，按照MOI＝10-20感染20BBZ病毒和20BBZIL7RaIL2Rg病毒，1天后换液继续细胞培养，按照每6天使用人工抗原呈递细胞或anti-hCD3/28刺激，经过2轮刺激后，所得细胞即为20BBZ CAR-T细胞和20BBZIL7RaIL2Rg CAR-T细胞，用于后续实验和表型分析。如图9所示， 所得细胞为CAR阳性。
实施例4-20BBZIL9RaIL2Rg CAR-T细胞的制备
本实施例所述的20BBZIL9RaIL2Rg CAR-T细胞的制备包括以下步骤：
1.慢病毒载体pCDH-MSCVEF-20BBZIL9RaIL2Rg的构建及病毒生产
将scFv-antihCD20-20BBZ(SEQ ID No.1)，IL9Ra胞内区(SEQ ID No.5)和IL2Rg胞内区(SEQ ID No.7)通过overlap PCR形成融合蛋白，两端加入EcoRI和BamHI酶切位点克隆pCDH-MSCVEF载体。将测序正确的克隆无内毒素大提，和慢病毒包装质粒(VSV-g，pMD Gag/Pol，RSV-REV)共同转染293X，48和72小时后收取上清，0.45uM过滤后，使用贝克曼超速离心机和SW28转头，25000RPM离心2小时浓缩病毒，即为pCDH-MSCVEF-20BBZIL9RaIL2Rg病毒(简称为20BBZIL9RaIL2Rg病毒)，用于后续CAR-T细胞生产。同时生产对照pCDH-MSCVEF-20BBZ病毒(简称20BBZ病毒)，将所得20BBZIL9RaIL2Rg病毒感染293细胞，测得病毒滴度，如图5所示。
2. 20BBZIL9RaIL2Rg CAR-T细胞和20BBZ CAR-T细胞的制备
将人PBMC经过Stemcell T细胞分离试剂盒纯化后，接种到anti-hCD3和anti-hCD28包被的96孔培养板，2天后，按照MOI＝10-20感染20BBZ病毒和20BBZIL9RaIL2Rg病毒，1天后换液继续细胞培养，按照每6天使用人工抗原呈递细胞或anti-hCD3/28刺激，经过2轮刺激后，所得细胞即为20BBZ CAR-T细胞和20BBZIL9RaIL2Rg CAR-T细胞，用于后续实验和表型分析。如图10所示，所得细胞为CAR阳性。
实施例5-20BBZIL21RaIL2Rg CAR-T细胞的制备
本实施例所述的20BBZIL21RaIL2Rg CAR-T细胞的制备包括以下步骤：
1.慢病毒载体pCDH-MSCVEF-20BBZIL21RaIL2Rg的构建及病毒生产
将scFv-antihCD20-20BBZ(SEQ ID No.1)，IL21Ra胞内区(SEQ ID No.6)和IL2Rg胞内区(SEQ ID No.7)通过overlap PCR形成融合蛋白，两端加入EcoRI和BamHI酶切位点克隆pCDH-MSCVEF载体。将测序正确的克隆无内毒素大提，和慢病毒包装质粒(VSV-g，pMD Gag/Pol，RSV-REV)共同转染293X，48和72小时后收取上清，0.45uM过滤后，使用贝克曼超速离心机和SW28转头，25000RPM离心2小时浓缩病毒，即为pCDH-MSCVEF-20BBZIL21RaIL2Rg病 毒(简称为20BBZIL21RaIL2Rg病毒)，用于后续CAR-T细胞生产。同时生产对照pCDH-MSCVEF-20BBZ病毒(简称20BBZ病毒)，将所得20BBZIL21RaIL2Rg病毒感染293细胞，测得病毒滴度，如图6所示。
2. 20BBZIL21RaIL2Rg CAR-T细胞和20BBZ CAR-T细胞的制备
将人PBMC经过Stemcell T细胞分离试剂盒纯化后，接种到anti-hCD3和anti-hCD28包被的96孔培养板，2天后，按照MOI＝10-20感染20BBZ病毒和20BBZIL21RaIL2Rg病毒，1天后换液继续细胞培养，按照每6天使用人工抗原呈递细胞或anti-hCD3/28刺激，经过2轮刺激后，所得细胞即为20BBZ CAR-T细胞和20BBZIL21RaIL2Rg CAR-T细胞，用于后续实验和表型分析。如图11所示，所得细胞为CAR阳性。
实施例6-比较20BBZ CAR-T细胞和20BBZIL7RaIL2Rg CAR-T细胞的扩增能力
将实施例3中步骤2制备所得的20BBZ CAR-T细胞和20BBZIL7RaIL2Rg CAR-T细胞，连续培养14天，每隔6天用人工抗原呈递细胞刺激一次，细胞计数，其结果如图12所示。由图可知，20BBZIL7RaIL2Rg CAR-T细胞相对20BBZCAR-T细胞有更强的增殖能力。
实施例7-比较20BBZ CAR-T细胞和20BBZIL7RaIL2Rg CAR-T细胞的肿瘤杀伤能力
将实施例3中步骤2制备所得的20BBZ CAR-T细胞和20BBZIL7RaIL2Rg CAR-T细胞，接种到96孔板，按照CAR-T：肿瘤细胞比例1:1、1:2、1:4加入Raji肿瘤细胞，24、48小时后比较肿瘤细胞的存活比例，其结果如图13所示。由图可知，20BBZIL7RaIL2Rg CAR-T细胞相对20BBZ CAR-T细胞有相似的肿瘤杀伤能力。
实施例8-比较20BBZ CAR-T细胞和20BBZIL7RaIL2Rg CAR-T细胞的抗肿瘤能力和体内存活能力
将10 6Nalm-6肿瘤细胞通过静脉接种到B-NDG小鼠，6天后给予10 7 20BBZ CAR-T细胞和20BBZIL7RaIL2Rg CAR-T细胞治疗，观察小鼠的存活率，部分小鼠在第7天检测其骨髓中的肿瘤细胞和CAR-T细胞的含量，其结果分别如图14和图15所示。由图可知，20BBZIL7RaIL2Rg CAR-T细胞相对20BBZ CAR-T细 胞显著延长了小鼠的生存，并在体内扩增更多。
由上述实施例可知，本发明通过构建新型含第三信号受体的CAR-T细胞，相对目前临床使用的CAR-T技术，其使CAR-T细胞在肿瘤中的活化能力、存活能力、扩增能力显著增强，具有更优异的抗肿瘤疗效。
以上对本发明的具体实施例进行了详细描述，但其只作为范例，本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言，任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此，在不脱离本发明的精神和范围下所作的均等变换和修改，都应涵盖在本发明的范围内。

Claims (10)

  1. 一种包含第三信号受体的嵌合抗原受体，其特征在于，所述嵌合抗原受体的结构为scFv(X)-(Y)CD3zeta-MN；
    其中，X包括肿瘤靶向抗体或能与肿瘤特异结合的配体、受体；
    Y为共刺激受体的胞内区，所述共刺激受体选自ICOS、CD28、CD27、HVEM、LIGHT、CD40L、4-1BB、OX40、DR3、GITR、CD30、TIM1、SLAM、CD2、CD226；
    M为gamma chain家族细胞因子受体的胞内区，所述细胞因子受体选自IL2Ra、IL2Rb、IL4Ra、IL7Ra、IL9Ra、IL15Ra、IL21Ra；
    N为IL2Rg胞内区。
  2. 根据权利要求1所述的一种包含第三信号受体的嵌合抗原受体，其特征在于，所述X选自anti-CD19抗体、anti-CD20抗体、EGFR抗体、HER2抗体、EGFRVIII抗体、anti-PSMA抗体、anti-BCMA抗体、anti-CD22抗体、anti-CD30抗体。
  3. 根据权利要求1所述的一种包含第三信号受体的嵌合抗原受体，其特征在于，所述X为anti-CD20抗体，所述Y为4-1BB胞内区，所述M选自IL2Rb胞内区、IL4Ra胞内区、IL7Ra胞内区、IL9Ra胞内区、IL21Ra胞内区中的一种。
  4. 根据权利要求3所述的一种包含第三信号受体的嵌合抗原受体，其特征在于，所述scFv(X)-(Y)CD3zeta为scFv-antihCD20-20BBZ，其序列如SEQ ID No.1所示；所述IL7Ra胞内区的序列如SEQ ID No.2所示；所述IL2Rb胞内区的序列如SEQ ID No.3所示；所述IL4Ra胞内区的序列如SEQ ID No.4所示；所述IL9Ra胞内区的序列如SEQ ID No.5所示；所述IL21Ra胞内区的序列如SEQ ID No.6所示；所述IL2Rg胞内区的序列如SEQ ID No.7所示。
  5. 一种由如权利要求1～4中任一项所述的嵌合抗原受体的重组表达载体构建的CAR-T细胞。
  6. 一种如权利要求5所述的CAR-T细胞的制备方法，其特征在于，包括如下步骤：
    步骤一、慢病毒载体的构建及病毒生产；
    将scFv(X)-(Y)CD3zeta，M和N形成融合蛋白，两端加入慢病毒载体，并和慢病毒包装质粒共同转染，获得scFv(X)-(Y)CD3zeta-MN病毒；
    步骤二、scFv(X)-(Y)CD3zeta-MN CAR-T细胞的制备；
    分离纯化后的人PBMC经过培养后，感染步骤一获得的scFv(X)-(Y)CD3zeta-MN病毒，在合适的条件下进行细胞扩增，制备scFv(X)-(Y)CD3zeta-MN CAR-T细胞。
  7. 根据权利要求6所述的CAR-T细胞的制备方法，其特征在于，所述慢病毒载体的构建及病毒生产的具体步骤包括：
    将scFv(X)-(Y)CD3zeta，M和N通过overlap PCR形成融合蛋白，两端加入酶切位点克隆慢病毒载体；将测序正确的克隆无内毒素大提，和慢病毒包装质粒共同转染，预定时间后收取上清，过滤、离心浓缩病毒，获得scFv(X)-(Y)CD3zeta-MN病毒。
  8. 根据权利要求6所述的CAR-T细胞的制备方法，其特征在于，所述scFv(X)-(Y)CD3zeta-MN CAR-T细胞的制备的具体步骤包括：将人PBMC经过分离纯化后，接种到具有合适刺激条件的培养板，培养预定时间后，感染步骤一生产的scFv(X)-(Y)CD3zeta-MN病毒，按照合适的刺激条件进行细胞扩增，经过2轮刺激扩增后，获得的细胞即为scFv(X)-(Y)CD3zeta-MN CAR-T细胞。
  9. 一种含有如权利要求5所述的CAR-T细胞的制剂。
  10. 如权利要求1～4中任一项所述的嵌合抗原受体，如权利要求5所述的CAR-T细胞在制备治疗或预防肿瘤药物中的应用。
PCT/CN2019/077923 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用 WO2019242339A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN202210196195.6A CN114516922A (zh) 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用
EP19823459.3A EP3812401A4 (en) 2018-06-20 2019-03-13 CHIMERIC ANTIGEN RECEPTOR WITH A THIRD SIGNAL RECEPTOR AND USE THEREOF
CN201980041282.0A CN112673025B (zh) 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用
JP2020571580A JP7433656B2 (ja) 2018-06-20 2019-03-13 第３シグナル受容体を含むキメラ抗原受容体およびその使用
KR1020217001094A KR20210023991A (ko) 2018-06-20 2019-03-13 제3 신호 수용체를 포함하는 키메릭 항원 수용체 및 이의 용도
US17/127,283 US11524034B2 (en) 2018-06-20 2020-12-18 Chimeric antigen receptor comprising third signal receptor and use thereof
US18/047,750 US20230134345A1 (en) 2018-06-20 2022-10-19 Chimeric antigen receptor comprising third signal receptor and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810636414.1 2018-06-20
CN201810636414.1A CN110615843B (zh) 2018-06-20 2018-06-20 一种包含第三信号受体的嵌合抗原受体及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/127,283 Continuation US11524034B2 (en) 2018-06-20 2020-12-18 Chimeric antigen receptor comprising third signal receptor and use thereof

Publications (1)

Publication Number Publication Date
WO2019242339A1 true WO2019242339A1 (zh) 2019-12-26

Family

ID=68920806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/077923 WO2019242339A1 (zh) 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用

Country Status (6)

Country Link
US (1) US11524034B2 (zh)
EP (1) EP3812401A4 (zh)
JP (1) JP7433656B2 (zh)
KR (1) KR20210023991A (zh)
CN (3) CN110615843B (zh)
WO (1) WO2019242339A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021207150A1 (en) * 2020-04-06 2021-10-14 Celledit Llc Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling
EP4083073A4 (en) * 2020-02-28 2023-07-12 Nanjing Bioheng Biotech Co., Ltd NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
CN111518219B (zh) * 2020-05-08 2021-06-22 浙江大学 嵌合性抗原受体及表达其的巨噬细胞、调节巨噬细胞极化的方法和应用
CN112062864A (zh) * 2020-09-18 2020-12-11 樊克兴 靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用
WO2023274355A1 (zh) * 2021-07-02 2023-01-05 上海交通大学 改造的间充质干细胞和免疫效应细胞联合治疗肿瘤
AU2022346040A1 (en) * 2021-09-17 2024-03-14 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors comprising interleukin-9 receptor signaling domain
WO2023133360A2 (en) * 2022-01-10 2023-07-13 Phenomic Ai Anti-collagen triple helix repeat containing 1 (cthrc1) antibodies and methods of using the same
CN117402231B (zh) * 2023-12-14 2024-04-09 南方医科大学南方医院 一种自发传递il-21信号的受体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582699A (zh) * 2011-04-08 2014-02-12 贝勒医学院 使用嵌合细胞因子受体逆转肿瘤微环境的影响
CN105777911A (zh) * 2016-04-12 2016-07-20 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
WO2017173256A1 (en) * 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112430580A (zh) * 2012-10-02 2021-03-02 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
CN103820393B (zh) * 2014-02-24 2016-09-07 西比曼生物科技（上海）有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用
ES2857998T3 (es) * 2015-02-12 2021-09-29 Univ Health Network Receptores de antígenos quiméricos
US11248058B2 (en) * 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
MX2018001182A (es) * 2015-07-28 2018-04-20 Univ Pennsylvania Monocitos/macrofagos modificados que expresan receptores de antigeno quimerico y sus usos.
GB201514875D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Receptor
CN105949317B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗cd20嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
EP3445847B1 (en) * 2016-04-20 2024-06-05 Fred Hutchinson Cancer Center Immunomodulatory il2r fusion proteins and uses thereof
CN106397608A (zh) * 2016-10-19 2017-02-15 中国医学科学院血液病医院（血液学研究所） Cd20特异性嵌合抗原受体及其应用
IL266628B1 (en) * 2016-11-17 2024-02-01 Bluebird Bio Inc TGFBeta signal converter
CN107058234B (zh) * 2017-05-12 2019-09-13 常州市第一人民医院 Car.il-33-t及其制备与应用
CN107245106B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
CN107384870A (zh) * 2017-07-31 2017-11-24 时力生物科技（北京）有限公司 一种靶向pd‑l1嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582699A (zh) * 2011-04-08 2014-02-12 贝勒医学院 使用嵌合细胞因子受体逆转肿瘤微环境的影响
WO2017173256A1 (en) * 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
CN105777911A (zh) * 2016-04-12 2016-07-20 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3812401A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4083073A4 (en) * 2020-02-28 2023-07-12 Nanjing Bioheng Biotech Co., Ltd NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
WO2021207150A1 (en) * 2020-04-06 2021-10-14 Celledit Llc Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling

Also Published As

Publication number Publication date
KR20210023991A (ko) 2021-03-04
CN112673025B (zh) 2022-04-01
US11524034B2 (en) 2022-12-13
JP2021529176A (ja) 2021-10-28
US20210169933A1 (en) 2021-06-10
CN110615843B (zh) 2023-05-09
JP7433656B2 (ja) 2024-02-20
CN112673025A (zh) 2021-04-16
EP3812401A4 (en) 2022-04-20
CN114516922A (zh) 2022-05-20
CN110615843A (zh) 2019-12-27
EP3812401A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
WO2019242339A1 (zh) 一种包含第三信号受体的嵌合抗原受体及其应用
CN110818802B (zh) 一种嵌合t细胞受体star及其应用
KR20200023165A (ko) 단일 도메인 항체에 기반한 bcma 키메라 항원 수용체 및 응용
CN113087806B (zh) 靶向多种肿瘤的新型car-t细胞及其制备和方法
WO2019195017A1 (en) Bcma-car-t cells
WO2022007650A1 (zh) 靶向bcma和cd19的嵌合抗原受体car或car构建体及其应用
CN110204619B (zh) 包含FcγRⅠ的嵌合抗原受体及其应用
CN109321530B (zh) 一种安全型嵌合抗原受体t细胞及其用途
CN113637087A (zh) 一种提高细胞免疫疗法安全性的嵌合受体和细胞
US11590168B2 (en) Chimeric antigen receptor comprising co-stimulatory receptor and application thereof
CN110699371A (zh) 一种基于FcγRⅢa的嵌合基因及其用途
US20210108175A1 (en) Universal car-t cell and preparation method and use thereof
Perera Molligoda Arachchige NK cell-based therapies for HIV infection: Investigating current advances and future possibilities
JP2023522112A (ja) 汎用型ヒト化ｃａｒ１９－ｄｎｔ細胞を製造する技術およびその使用
US20230134345A1 (en) Chimeric antigen receptor comprising third signal receptor and use thereof
US20230277666A1 (en) Chimeric antigen receptor comprising co-stimulatory receptor and application thereof
CN117645670A (zh) 一种新型嵌合抗原受体及其用途
CN116162168A (zh) 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用
CN109970862A (zh) 一种携带Beacon标签的嵌合抗原受体T细胞改造技术

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19823459

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020571580

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217001094

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019823459

Country of ref document: EP

Effective date: 20210120